Introgen's Advexin Demonstrates Clinical Benefit in Inherited Cancer
AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--IntrogenTherapeutics, Inc. (NASDAQ:INGN) announced today the publication ofdata describing the dramatic clinical benefit of its lead productAdvexin in a patient with a rare inherited form of cancer known asLi-Fraumeni Syndrome (LFS), a genetic disorder characterized byinherited mutations i...Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - Introgen Therapeutics,Inc. (NASDAQ:INGN) reported updated ADVEXIN(R) biomarker data overthe weekend in Los Angeles, California at the Annual Meeting of theAmerican Association for Cancer Research. Abnormality of the p53 tumor suppressor is one of the mostcommon and fundamental molecular defects in cancer. ADVEXIN'smechanism of action is targete...